Neurocrine Biosciences | Ventes

Sales Changement Date
AbbVie USD 12.31B 1.99B 2024-03
Acadia Pharmaceuticals USD 205.8M 25.24M 2024-03
Agios Pharmaceuticals USD 8.19M 1.09M 2024-03
ALKERMES USD 350.4M 27.08M 2024-03
Alnylam Pharmaceuticals USD 494.33M 54.61M 2024-03
Amgen USD 7.45B 746M 2024-03
Biogen USD 2.29B 96.3M 2024-03
BioMarin Pharmaceutical USD 649M 2.79M 2024-03
Cytokinetics USD 840K 832K 2024-03
Dynavax Technologies USD 50.79M 18.72M 2024-03
Exelixis USD 425M 54.65M 2024-03
Gilead Sciences USD 7.12B 64M 2023-12
Halozyme Therapeutics USD 196M 34.04M 2024-03
Incyte USD 880.89M 132.45M 2024-03
Intra Cellular Therapies USD 144.84M 12.74M 2024-03
Ionis Pharmaceuticals USD 119M 206M 2024-03
Neurocrine Biosciences USD 515.3M 100K 2024-03
Pfizer USD 14.9B 651M 2024-03
Prothena USD 316K 84.55M 2023-12
Regeneron Pharmaceuticals USD 3.15B 284.3M 2024-03
Repligen USD 151.3M 4.44M 2024-03
Sarepta Therapeutics USD 413.5M 16.72M 2024-03
Teva Pharmaceutical Industries USD 14.13B 9.67B 2024-03
Ultragenyx Pharmaceutical USD 108.8M 18.59M 2024-03
Vertex Pharmaceuticals USD 2.69B 172.3M 2024-03



Neurocrine Biosciences Ventes - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2024.